cyclophilin
cypa
ubiquit
cellular
enzym
play
critic
role
mani
biolog
process
inhibitor
report
potenti
immunosuppress
activ
work
report
novel
quinoxalin
deriv
ndiethylcarbamoylpiperidino
carbonylamino
quinoxalin
confirm
potent
inhibitor
human
cypa
use
surfac
plasmon
reson
spr
fluoresc
titrat
techniqu
kinet
analysi
interact
quantit
perform
cypa
peptidyl
prolyl
cistran
isomeras
ppias
activ
inhibit
assay
show
demonstr
highli
cypa
ppias
inhibitori
activ
vivo
assay
result
show
could
inhibit
mous
spleen
cell
prolifer
induc
concanavalin
con
molecular
dock
simul
elucid
specif
bind
cypa
atom
level
current
work
provid
use
inform
discoveri
immunosuppressor
base
cypa
inhibitor
one
novel
quinoxalin
deriv
potent
human
cyclophilin
inhibitor
show
highli
inhibitori
activ
mous
spleen
cell
prolifer
cyclophilin
cypa
belong
solubl
cytoplasm
immunophilin
catalyz
cistran
isomer
peptidylprolyl
bond
act
molecular
chaperon
play
assist
role
protein
fold
assembl
transport
process
cypa
could
also
serv
intracellular
receptor
function
cell
life
like
immunophilin
cypa
high
bind
affin
immunosuppressor
cyclosporin
csa
csa
inhibit
peptidylprolyl
cistran
isomeras
activ
cypa
cypa
wide
distribut
variou
tissu
express
highest
concentr
brain
make
import
matur
fold
neuronspecif
protein
vivo
even
though
detail
function
mechan
larg
unknown
report
csa
regul
level
cypa
undifferenti
campinduc
differenti
murin
neuroblastoma
nb
cell
cultur
treat
csa
nb
cell
partial
differenti
neuron
implic
role
cypa
neuron
differenti
therefor
cypa
ligand
might
hold
great
potenti
treatment
nerv
injuri
neurolog
diseas
csa
natur
fungal
cyclic
undecapeptid
metabolit
use
immunosuppress
drug
prevent
organ
reject
transplant
oper
csainduc
immunosuppress
tent
explain
relat
cypa
believ
immunosuppress
action
exercis
ternari
complex
name
csacypa
complex
inhibit
calcineurin
cn
activ
play
key
role
signal
transduct
pathway
toward
tcell
activ
inhibit
cn
might
prevent
dephosphoryl
cytosol
compon
transcript
factor
nuclear
factor
activ
cell
nfat
prevent
movement
nucleu
critic
product
immunosignal
cytokin
includ
interleukin
thu
lead
suppress
tcell
activ
cypa
also
requir
infecti
activ
human
immunodefici
viru
type
gag
hiv
polyprotein
cleav
proteas
sever
function
protein
matrix
capsid
ca
nucleocapsid
nc
small
peptid
hiv
ca
protein
essenti
assembl
infect
hiv
virion
cypa
bind
directli
ca
domain
gag
cacypa
stoichiometri
approxim
per
virion
format
cacypa
complex
competit
inhibit
molecul
bind
activ
site
cypa
includ
csa
nonimmunosuppress
analogu
sdz
nim
complex
format
also
inhibit
seri
mutat
nterminu
ca
reagent
mutat
inhibit
cacypa
interact
vitro
also
block
cypa
packag
replic
cultur
demonstr
interact
essenti
viral
infect
recent
found
nucleocapsid
n
protein
sarscov
bind
human
cypa
high
affin
equilibrium
dissoci
k
time
higher
bind
affin
ca
cypa
sequenc
align
molecular
model
reveal
sarscov
n
loop
fit
activ
site
groov
cypa
hydrogen
bond
cationp
hydrogen
bond
interact
observ
sarscov
ncypa
interact
might
provid
new
hint
understand
possibl
sarscov
infect
pathway
human
cell
suppli
feasibl
approach
antisar
agent
screen
taken
togeth
cypa
involv
mani
diseas
viru
invas
drug
discoveri
effort
focus
develop
cypa
inhibitor
pharmaceut
research
current
work
report
novel
quinoxalin
deriv
ndiethylcarbamoylpiperidino
carbonylamino
quinoxalin
confirm
potent
human
cypa
inhibitor
vivo
assay
result
show
high
inhibit
activ
mous
spleen
cell
prolifer
elucid
bind
cypa
atom
level
molecular
dock
simul
bind
also
well
perform
experiment
comput
result
provid
use
inform
discoveri
immunosuppressor
target
cypa
discov
activ
compound
might
use
possibl
lead
compound
research
gener
compound
prepar
accord
synthet
strategi
outlin
scheme
quinoxalin
obtain
accord
literatur
method
reaction
triphosgen
nitrogen
room
temperatur
presenc
triethylamin
afford
target
compound
synthes
reaction
n
ndiethylnipecotamid
structur
confirm
ir
h
nmr
ms
spectral
analys
address
kinet
data
compound
bind
cypa
spr
technolog
base
biacor
instrument
use
immobil
cypa
biacor
biosensor
chip
result
reson
signal
reson
unit
ru
shown
figur
biosensor
ru
concentrationdepend
suggest
bind
cypa
vitro
langmuir
bind
model
thu
use
determin
equilibrium
dissoci
constant
k
associ
k
dissoci
k
rate
constant
eq
wherer
repres
respons
unit
c
concentr
analyt
obtain
result
evalu
v
statist
valu
biacor
kinet
paramet
list
tabl
spr
result
show
compound
exhibit
strong
bind
affin
cypa
k
valu
lm
k
valu
found
good
agreement
appar
equilibrium
dissoci
constant
k
intrins
fluoresc
titrat
analysi
ic
valu
cyclophilin
ppias
activ
inhibit
determin
suggest
spr
assay
power
use
method
screen
cypa
inhibitor
state
publish
result
trytophan
residu
around
cypa
bind
site
could
use
intrins
probe
studi
interact
cypa
ligand
therefor
investig
bind
affin
compound
cypa
use
publish
intrins
fluoresc
titrat
techniqu
assay
stoichiometri
cypacompound
bind
perform
accord
publish
result
cypacsa
interact
appar
equilibrium
dissoci
constant
k
bind
thu
calcul
accord
literatur
method
assum
occup
cypa
set
fraction
fluoresc
chang
fc
point
concentr
bound
ligand
equal
bound
protein
half
total
concentr
protein
accordingli
k
equal
total
ligand
concentr
fc
minu
concentr
bound
protein
figur
show
typic
tryptophan
fluoresc
quench
cypa
induc
titrat
increas
concentr
sinc
compound
show
intrins
fluoresc
absorpt
possibl
effect
experi
could
neglect
obvious
evalu
k
valu
lm
compat
k
valu
biacor
moreov
indic
figur
tabl
fact
perturb
csa
bind
cypa
competit
assay
shift
k
lm
cypa
bind
csa
implic
csa
bind
cypa
bind
pocket
agreement
molecular
dock
analysi
result
work
discuss
blow
sinc
cypa
belong
famili
peptidyl
prolyl
cistran
isomeras
ppias
classic
spectrophotometr
method
could
use
determin
ppias
inhibit
activ
test
compound
cypa
assay
rate
constant
cistran
interconvers
evalu
fit
data
integr
firstord
rate
equat
nonlinear
leastsquar
analysi
csa
test
posit
control
assay
assess
ic
csa
cypa
figur
nm
fig
agreement
previou
result
inhibit
result
compound
cypa
ppias
activ
seri
concentr
demonstr
figur
ic
valu
thu
determin
lm
compar
biacor
fluoresc
titrat
analyt
result
tabl
result
therebi
impli
reliabl
three
detect
approach
test
immunosuppress
effect
antiprolifer
activ
mous
spleen
cell
compound
determin
assay
csa
use
control
evalu
inhibit
activ
demonstr
figur
inhibit
prolifer
spleen
cell
result
increas
compound
concentr
ic
valu
csa
found
lm
lm
respect
investig
possibl
compound
toxic
csa
spleen
cell
effect
cell
caus
treatment
h
csa
lm
lm
assay
od
lm
lm
csa
medium
p
od
lm
medium
p
notic
treatment
csa
lm
lm
lm
show
signific
influenc
viabil
naiv
spleen
cell
lm
show
appar
influenc
cell
viabil
data
shown
result
therebi
impli
cytotox
probabl
less
csa
might
use
possibl
lead
compound
immunosuppress
agent
discoveri
gain
insight
interact
model
atom
level
dock
simul
bind
carri
use
human
cypa
crystal
structur
pdb
entri
model
bind
pocket
cypa
fairli
big
shallow
compos
residu
molecular
dock
result
indic
bind
activ
site
groov
cypa
similar
csa
differ
case
full
occup
csa
took
partli
bind
pocket
might
swing
pocket
bind
model
cypa
shown
figur
work
report
one
small
molecul
quinoxalin
deriv
novel
cypa
inhibitor
vivo
assay
indic
compound
inhibit
mous
spleen
cell
prolifer
induc
concanavalin
use
spr
fluoresc
titrat
techniqu
kinet
analys
interact
quantit
perform
measur
ic
valu
good
agreement
spr
fluoresc
titrat
result
suggest
power
approach
identifi
cypa
inhibitor
molecular
dock
result
elucid
specif
bind
cypa
atom
level
current
work
provid
use
inform
discoveri
immunosuppressor
target
cypa
might
use
lead
compound
research
reaction
carri
use
ovendri
roundbottom
flask
atmospher
nitrogen
unless
otherwis
note
mixtur
stir
magnet
dichloromethan
distil
cah
triethylamin
distil
sodium
ir
spectra
kbr
disk
obtain
nicoletmagna
peak
wavenumb
greater
cm
report
h
nuclear
magnet
reson
nmr
spectra
mhz
record
cdcl
solut
bruker
instrument
prepar
depict
scheme
quinoxalin
obtain
describ
literatur
reaction
quinoxalin
triphosgen
nitrogen
room
temperatur
dichloromethan
present
triethylamin
afford
n
ndiethylnipecotamid
ad
reaction
mixtur
afford
target
compound
purifi
flash
chromatographi
silica
gel
ethyl
acet
clone
techniqu
includ
polymeras
chain
reaction
pcr
restrict
ligat
escherichai
coli
transform
plasmid
dna
prepar
carri
accord
standard
method
histag
cypa
protein
express
purifi
plasmid
accord
publish
procedur
interact
compound
cypa
perform
use
dual
flow
cell
biacor
instrument
biacor
ab
uppsala
sweden
experi
carri
use
hbsep
mm
acid
hepe
mm
nacl
mm
edta
surfact
ph
run
buffer
constant
flow
rate
llmin
protein
immobil
directli
coval
hydrophil
carboxymethyl
dextran
matrix
sensor
chip
biacor
use
standard
primari
amin
coupl
reaction
protein
bound
sensor
chip
dilut
mm
sodium
acet
buffer
ph
concentr
lm
concentr
compound
dissolv
run
buffer
vari
lm
data
analys
carri
use
biaevalu
softwar
sensorgram
process
automat
correct
nonspecif
bulk
refract
index
effect
kinet
analys
ligand
bind
protein
perform
base
langmuir
bind
fit
model
accord
procedur
describ
softwar
manual
fluoresc
measur
perform
hitachi
tokyo
japan
fluoresc
spectrophotomet
equip
thermal
control
chang
intrins
tryptophan
fluoresc
compound
bound
protein
cypa
monitor
use
procedur
similar
describ
literatur
experi
carri
mm
trishcl
mm
nacl
ph
protein
concentr
set
lm
compound
concentr
vari
lm
compound
prepar
dimethylsulfoxid
dmso
stock
solut
mm
excit
wavelength
set
nm
emiss
rang
nm
nm
slit
set
nm
fluoresc
read
taken
wavelength
maximum
emiss
gener
nm
result
fluoresc
chang
convers
fraction
maxim
chang
plot
versu
total
concentr
ligand
cypa
ppias
activ
measur
use
standard
chymotrypsincoupl
assay
assay
buffer
mm
hepe
mm
nacl
ph
cypa
nm
stock
solut
precool
ad
mgml
chymotrypsin
mm
hcl
reaction
initi
ad
mm
peptid
substrat
sucalaalacisprophepna
liclthf
solut
rapid
invers
delay
onset
mix
usual
absorb
pnitroanilin
follow
nm
reaction
complet
min
final
concentr
licl
assay
mm
thf
present
concentr
vv
absorb
read
collect
everi
spectrophotomet
progress
curv
analyz
nonlinear
leastsquar
fit
inhibit
assay
compound
perform
manner
mention
aliquot
compound
dmso
ad
cypa
solut
assay
buffer
preincub
h
assay
start
addit
chymotrypsin
substrat
calcul
halfmaxim
inhibitori
concentr
ic
percent
remain
ppias
activ
plot
common
logarithm
compound
concentr
data
fit
use
sigmoid
fit
model
softwar
femal
icr
strain
mice
week
old
g
purchas
experiment
anim
hous
china
pharmaceut
univers
nanj
china
maintain
plastic
cage
free
access
pellet
food
water
h
lightdark
cycl
studi
compli
current
ethic
regul
anim
research
nanj
univers
mice
use
treat
human
spleen
asept
taken
mice
crush
gentli
separ
singl
cell
squeez
ml
dhank
solut
gibco
brl
cell
obtain
pass
eightlay
gauz
centrifug
revmin
min
pellet
ad
ml
steril
tri
hydroxymethyl
aminomethan
contain
nh
cl
ph
follow
centrifug
remov
erythrocyt
wash
twice
rpmi
contain
uml
penicillin
uml
streptomycin
fetal
calf
serum
fc
rpmi
medium
resuspend
rpmi
medium
use
cell
cultur
spleen
cell
cultur
flatbottom
micropl
falcon
densiti
cellswel
rpmi
medium
ml
stimul
lgml
cona
h
co
air
presenc
absenc
control
group
variou
concentr
compound
cell
growth
evalu
modifi
mtt
assay
briefli
mgml
mtt
rpmi
ad
h
incub
remov
supernat
dmso
ad
dissolv
formazan
crystal
plate
shaken
min
read
elisa
reader
sunris
remotetouch
screen
tecan
austria
nm
assay
run
triplic
effect
compound
prolifer
mous
spleen
cell
induc
con
calcul
eq
inhibitori
rate
compound
data
express
mean
sd
signific
differ
group
statist
analysi
evalu
oneway
analysi
varianc
follow
student
twotail
ttest
evalu
differ
two
group
dunnett
ttest
control
group
multipl
dose
group
oneway
analysi
varianc
reveal
signific
effect
p
crystal
structur
cypa
complex
sanglifehrin
macrolid
sfm
pdb
entri
recov
protein
data
bank
http
wwwrcsborg
pdb
use
target
molecular
model
dock
three
dimension
structur
compound
construct
scratch
sybyl
optim
energi
converg
tripo
forc
field
charg
present
studi
program
employ
primari
molecular
dock
residu
cypa
around
sfm
radiu
isol
construct
grid
dock
calcul
result
substructur
includ
residu
bind
pocket
dock
calcul
kollmanallatom
charg
assign
protein
gasteigermarsili
partial
charg
assign
small
molecul
surfac
structur
bind
pocket
construct
use
molcad
modul
sybyl
dock
suit
program
design
find
possibl
orient
ligand
receptor
site
orient
ligand
evalu
shapescor
function
andor
function
approxim
ligand
receptor
bind
energi
shapescor
function
empir
function
resembl
van
der
waal
attract
energi
ligandreceptor
bind
energi
taken
approxim
sum
van
der
waal
electrostat
interact
energi
initi
orient
score
evalu
gridbas
rigid
bodi
minim
carri
ligand
locat
nearest
local
energi
minimum
within
receptor
bind
site
posit
conform
dock
molecul
optim
use
singl
anchor
search
torsion
minim
method
dock
thirti
conform
per
ligand
build
cycl
maximum
anchor
orient
use
anchorfirst
dock
algorithm
dock
configur
energi
minim
use
maximum
iter
one
minim
cycl
